Phase II, Multicenter, Simon Two-Stage Study of R788 in Patients With Relapsed or Refractory T-Cell Lymphoma.

Trial Profile

Phase II, Multicenter, Simon Two-Stage Study of R788 in Patients With Relapsed or Refractory T-Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 26 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top